Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 1 of 2: Normalized growth rate inhibition values - Dataset (ID:20343)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration (uM) | Primary Target | Pathway | Mean Normalized Growth Rate Inhibition Value | Increased Fraction Dead |
|---|---|---|---|---|---|---|
| HCC1806 | Everolimus | 3.1623 | mTOR1 | PI3K/mTOR | 0.8168 | -0.00407 |
| HCC1806 | Pictilisib | 3.1623 | pan PI3K | PI3K/mTOR | 0.7587 | 0.01597 |
| HCC1806 | Bleomycin | 3.1623 | Radiation | Misc | 0.6374 | 0.05149 |
| HCC1806 | TGX221 | 3.1623 | PI3Kb | PI3K/mTOR | 1.0207 | -0.00297 |
| HCC1806 | PF-4708671 | 3.1623 | p70S6K | PI3K/mTOR | 1.1503 | -0.01604 |
| HCC1806 | Buparlisib | 3.1623 | pan PI3K | PI3K/mTOR | -0.1855 | 0.49892 |
| HCC1806 | Dasatinib | 3.1623 | BCR/ABL | MAPK/nRTK | -0.0635 | 0.25574 |
| HCC1806 | Olaparib | 3.1623 | PARP | Misc | 0.8180 | 0.02674 |
| HCC1806 | Ipatasertib | 3.1623 | AKT | PI3K/mTOR | 0.9502 | -0.00032 |
| HCC1806 | Taselisib | 3.1623 | PI3Ka, g, d | PI3K/mTOR | 0.4011 | 0.10718 |
| HCC1806 | INK-128 | 3.1623 | mTORC1/2 | PI3K/mTOR | 0.2620 | 0.10078 |
| HCC1806 | Vorinostat | 3.1623 | HDAC | Misc | 0.1581 | 0.17812 |
| HCC1806 | A-1210477 | 3.1623 | Mcl-1 | Misc | 1.0029 | -0.00692 |
| HCC1806 | Doxorubicin | 3.1623 | Chemo | Chemotherapy | -0.3241 | 0.57687 |
| HCC1806 | Abemaciclib | 3.1623 | CDK4/6 | Cell cycle | 0.1267 | 0.14911 |
| HCC1806 | Cisplatin | 3.1623 | Chemo | Chemotherapy | -0.1138 | 0.28875 |
| HCC1806 | Palbociclib | 3.1623 | CDK4/6 | Cell cycle | 0.7848 | 0.00614 |
| HCC1806 | AZD7762 | 3.1623 | CHK1/2 | Cell cycle | -0.3761 | 0.66396 |
| HCC1806 | Topotecan | 3.1623 | Topo I | Chemotherapy | -0.5081 | 0.50830 |
| HCC1806 | ABT-737 | 3.1623 | Bcl2/XL | Misc | 1.1888 | 0.00960 |
| HCC1806 | Alpelisib | 3.1623 | PI3Ka | PI3K/mTOR | 0.8853 | 0.01047 |
| HCC1806 | Saracatinib | 3.1623 | SRC | MAPK/nRTK | 0.4325 | 0.11326 |
| HCC1806 | Etoposide | 3.1623 | Topo II | Chemotherapy | -0.4171 | 0.47329 |
| HCC1806 | Neratinib | 3.1623 | EGFR/HER2 | RTK | -0.0883 | 0.43583 |
| HCC1806 | Ceritinib | 3.1623 | ALK | RTK | 0.1763 | 0.12321 |